Compare First Solar, Inc. (FSLR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Johnson & Johnson — how do they compare? First Solar, Inc. trades at $177.82 (market cap $19.22B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 32.2× First Solar, Inc.'s market cap, and Johnson & Johnson pays a 2.09% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Johnson & Johnson for 129 Days on average.
| FSLR | JNJ | |
|---|---|---|
Market Cap | $19.22B | $618.09B |
Volume | 2,067,793 | 6,050,983 |
Sector | Energy | Health |
52-Week High | $318.30 | $278.43 |
52-Week Low | $172.11 | $186.00 |
Typical Hold Time | 76 Days | 129 Days |
Enterprise Value | $17.69B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $177.82, down 1.28% on the day, amid a bearish technical signal and recent sector-wide pressures. The stock shows strong fundamentals with a P/E of 11.03, net income margin of 32.47%, and robust cash flow from operations of $2.06B in 2025. Recent news includes a patent infringement lawsuit filed on October 1, 2026, which briefly lifted the stock, while high put option volume on October 3, 2026, indicates investor caution.
FSLR presents a mixed outlook: solid profitability and analyst consensus support a 'Moderate Buy' with a $267.59 price target, but technical weakness and solar sector headwinds from high borrowing costs pose near-term risks. The stock's 44.9% decline from its all-time high highlights volatility, yet earnings beats in Q1 and Q2 2026 underscore operational strength.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
